02.17.20
ChromaDex Corp. has launched its flagship cellular health supplement Tru Niagen (nicotinamide riboside) as a product offering in Nestlé Health Science’s (NHSc) personalized nutrition service Persona Nutrition. Persona is a personalized nutrition program that provides an online health assessment, a doctor-recommended vitamin routine, and monthly home delivery service.
There is an increasing amount of nutrition science available supporting the importance of maintaining the body’s NAD (nicotinamide adenine dinucleotide), a coenzyme important for cellular health, exercise, sleeping soundly and turning the food we eat into energy. ChromaDex’s patented Tru Niagen is clinically proven to increase NAD levels.
“We appreciate Persona’s focus on personalized health and customer experience for its subscribers,” said ChromaDex CEO Rob Fried. “Nestlé Health Science shares our commitment to science, and we are pleased to extend our partnership with them to include personalized nutrition.”
“Cellular health is at the core of the concept of beauty, from the inside out. As more health-conscious consumers want to optimize their health and wellness holistically, we are proud to partner with ChromaDex to offer its leading NAD-boosting Tru Niagen supplement to our customers,” said Persona CEO Jason Brown. “Tru Niagen is supported by published clinical studies and manufactured with the highest standard of safety and quality, which fits in nicely with our current portfolio of top-of-the-line nutritional supplements.”
In December 2018, ChromaDex entered into a license and supply agreement for NIAGEN (nicotinamide riboside) with Nestlé Health Science, a global leader in pioneering quality science-based nutritional health solutions. The agreement provides NHSc the exclusive right to include CDXC’s patented nicotinamide riboside ingredient Tru Niagen in NHSc branded medical nutrition, and co-exclusive rights to include Tru Niagen in certain products within the consumer health category.
Niagen is the only commercially available NR which has twice been successfully reviewed under U.S. Food & Drug Association's (FDA) new dietary ingredient (NDI) notification requirement and has also been successfully notified to the FDA as generally recognized as safe (GRAS).
ChromaDex has also secured regulatory approvals on its patent-protected ingredient in Canada, the European Union, and Australia.
There is an increasing amount of nutrition science available supporting the importance of maintaining the body’s NAD (nicotinamide adenine dinucleotide), a coenzyme important for cellular health, exercise, sleeping soundly and turning the food we eat into energy. ChromaDex’s patented Tru Niagen is clinically proven to increase NAD levels.
“We appreciate Persona’s focus on personalized health and customer experience for its subscribers,” said ChromaDex CEO Rob Fried. “Nestlé Health Science shares our commitment to science, and we are pleased to extend our partnership with them to include personalized nutrition.”
“Cellular health is at the core of the concept of beauty, from the inside out. As more health-conscious consumers want to optimize their health and wellness holistically, we are proud to partner with ChromaDex to offer its leading NAD-boosting Tru Niagen supplement to our customers,” said Persona CEO Jason Brown. “Tru Niagen is supported by published clinical studies and manufactured with the highest standard of safety and quality, which fits in nicely with our current portfolio of top-of-the-line nutritional supplements.”
In December 2018, ChromaDex entered into a license and supply agreement for NIAGEN (nicotinamide riboside) with Nestlé Health Science, a global leader in pioneering quality science-based nutritional health solutions. The agreement provides NHSc the exclusive right to include CDXC’s patented nicotinamide riboside ingredient Tru Niagen in NHSc branded medical nutrition, and co-exclusive rights to include Tru Niagen in certain products within the consumer health category.
Niagen is the only commercially available NR which has twice been successfully reviewed under U.S. Food & Drug Association's (FDA) new dietary ingredient (NDI) notification requirement and has also been successfully notified to the FDA as generally recognized as safe (GRAS).
ChromaDex has also secured regulatory approvals on its patent-protected ingredient in Canada, the European Union, and Australia.